Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 4,201
- 试验地点
- 1
- 主要终点
- All-cause mortality of COVID-19 patients
研究概览
简要总结
The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.
详细描述
4201 COVID-19 patients discharged from our hospital were enrolled. Binary logistic regression analysis and ROC curve were used to investigate the role of comorbidities, laboratory parameters and clinical manifestation on progression of COVID-19 patients. We used propensity-score models conditional on baseline characteristics and Univariate Cox regression model to examine whether Azvudine can reduce the mortality of COVID-19 patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The COVID-19 positive patients
排除标准
- •patients treated with both azvudine and monotamivir;
- •patients receiving other antiviral drugs such as nematavir/ritonavir;
- •age < 18 years old
研究组 & 干预措施
Azvudine group
Azvudine group included COVID-19 patients treated with azvudine antiviral therapy;
干预措施: Azvudine (Drug)
结局指标
主要结局
All-cause mortality of COVID-19 patients
时间窗: Time from onset to death
All-cause mortality of COVID-19 patients
次要结局
未报告次要终点